Observational Study to Evaluate the Clinical Impact of BTK Inhibitor-Based Regimens in Treatment-Naïve Patients With Mantle Cell Lymphoma (MCL) in Italian Clinical Practice.
An Observational Cohort Study to Evaluate the Clinical Impact of BTK Inhibitor-Based Regimens in Treatment-Naïve Patients With Mantle Cell Lymphoma (MCL) in Italian Clinical Practice.
Mantle cell lymphoma (MCL) is a subtype of B-cell non-Hodgkin lymphoma (B-NHL), characterized by a heterogeneous clinical course and, in a substantial proportion of patients, an aggressive disease behavior requiring timely and effective treatment at diagnosis.
In recent years, the therapeutic landscape of MCL has undergone a major transformation with the introduction of Bruton's tyrosine kinase inhibitors (BTKis). Ibrutinib, acalabrutinib, zanubrutinib, and the non-covalent BTKi pirtobrutinib have demonstrated substantial clinical activity in relapsed/refractry (R/R) MCL. Their role has progressively expanded beyond the relapsed/refractory setting, with BTK inhibitor-based regimens increasingly being incorporated into frontline treatment strategies, supported by emerging clinical trial evidence and reflected in evolving treatment guidelines and clinical practice.
Despite this rapidly evolving treatment landscape, real-world evidence on the use of BTKi-based regimens in the frontline setting remains limited. In particular, data on treatment selection, efficacy, safety, treatment duration, and management of toxicities in routine clinical practice are still scarce.
We therefore propose an observational cohort study to evaluate the clinical impact of previously untreated patients with MCL receiving frontline BTKi-based regimens in routine clinical practice in Italy. The study will assess treatment patterns, effectiveness, safety, and treatment persistence, providing real-world insights into the use of these strategies beyond clinical trials.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Uffici Studi FIL
- Telefonnummer: +390131033153
- E-Mail: startup@filinf.it
Studieren Sie die Kontaktsicherung
- Name: Uffici Studi FIL
- Telefonnummer: +390599769913
- E-Mail: gestionestudi@filinf.it
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Previously untreated patients with Mantle Cell Lymphoma receiving frontline Bruton's Tyrosin Kinase-based treatment in routine clinical practice in Italy.
Beschreibung
Inclusion criteria:
General Inclusion Criteria:
- Histologically confirmed diagnosis of mantle cell lymphoma (MCL) requiring treatment according to current clinical guidelines and standard-of-care recommendations.
- Age ≥ 18 years at the time of BTKi-based treatment initiation.
- Patients who are able to understand the nature and objectives of the study and who have provided written informed consent, approved by the Independent Ethics Committee (IEC), for participation in the observational study.
For the retrospective enrollment group:
In addition to the general inclusion criteria, patients included in the retrospective cohort must meet the following criterion:
● Patients eligible for BTKi-based treatment before the relevant marketing authorization (AIC) in Italy, includingthose treated through off-label use, compassionate use programs, or under Italian Law 648/96, as applicable.
For the prospective enrollment group:
In addition to the general inclusion criteria, patients included in the prospective cohort must meet the following criterion:
● Patients eligible for a BTKi-based regimen in accordance with the EMA-approved indication and the corresponding AIC in Italy.
Exclusion criteria:
- Diagnosis of a histological subtype of lymphoma other than mantle cell lymphoma (MCL).
- Concurrent participation in a prospective interventional clinical trial that may interfere with the assessment of treatment exposure, efficacy, safety, or other study endpoints.
- Inability or unwillingness to provide written informed consent, where required by applicable ethical and regulatory requirements.
- Any condition that, in the investigator's judgment, may preclude reliable collection or interpretation of study data or compromise the patient's ability to participate in the study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: CROSS_SECTIONAL
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
|---|
|
Retrospective enrollment group
Patients who had an indication for a BTKi-based regimen before the marketing authorization (AIC) in Italy. This group may include patients treated before the relevant AIC through off-label use, compassionate use programs, or treatment provided under Italian Law 648/96. |
|
Prospective enrollment group
Patients eligible for a BTKi-based regimen in accordance with the EMA approved indication and the corresponding AIC in Italy. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Best overall response
Zeitfenster: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined according to Lugano 2014 criteria as the best response recorded between the start of therapy and the end of treatment. Overall response rate (ORR) includes complete (CR) and partial response (PR). Patients without response assessment for any reason are considered non-responders. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Progression-free survival (PFS)
Zeitfenster: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined as the time from the start of BTKi-based treatment to the first documentation of relapse, progression or death from any cause. Patients alive without progression are censored at the date of last disease assessment. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Overall survival (OS)
Zeitfenster: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined as the time from the start of BTKi-based treatment to death from any cause. Patients alive are censored at the date of last contact. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Event-free survival (EFS)
Zeitfenster: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined as the time from the start of BTKi-based treatment to progression, death from any cause or initiation of a new anti-lymphoma treatment (NALT) without documented progression. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Time to next treatment (TTNT)
Zeitfenster: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined as the time from the start of BTKi-based treatment to the initiation of a NALT. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Duration of response (DOR)
Zeitfenster: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined in responding patients as the time from the first documentation of CR or PR to progression or death from any cause |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Non-relapse mortality (NRM)
Zeitfenster: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined as death without prior relapse or progression |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
POD24
Zeitfenster: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined as relapse or progression within 24 months from diagnosis (early POD) or later than 24 months (late POD) |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Incidence of adverse events
Zeitfenster: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Incidence of grade 3, 4 and 5 adverse events according to the latest NCI CTCAE version, and of serious adverse events, occurring after the first dose or at any time during therapy. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Incidence of deaths
Zeitfenster: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Deaths occurring during treatment, at the end of treatment, and during follow-up, with specific assessment of early deaths (defined as deaths occurring within 3 months from treatment initiation), treatment-related (toxic) deaths, and causes of death (any). |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Treatment duration
Zeitfenster: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Defined as the time from the start of BTKi-based treatment to permanent discontinuation for any reason. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Treatment discontinuation
Zeitfenster: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Incidence and reasons for treatment discontinuation (progression, toxicity, death, patient preference, physician decision, planned completion, other). |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
|
Treatment modifications
Zeitfenster: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Frequency and reasons for dose reductions, interruptions and other modifications. |
From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Marco Ladetto, MD, S.C.D.U. Ematologia, I.R.C.C.S. A.O.U. SS. Antonio e Biagio e Cesare Arrigo - Alessandria
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- FIL_MANTLE-FIRST-BTKi
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .